Skip to main content
SupplementScience

Benefits of AREDS2 Formula

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • AMD progression reduction — the AREDS2 trial (n=4,203, 5-year follow-up) showed approximately 25% reduction in progression to advanced AMD compared to placebo
  • Safer than original AREDS — replacing beta-carotene with lutein/zeaxanthin eliminated the lung cancer risk seen in smokers with the original formula
  • Long-term proven benefit — a 10-year follow-up confirmed sustained protective effects of the AREDS2 formulation, with lutein/zeaxanthin performing better than beta-carotene
  • Macular pigment support — the lutein/zeaxanthin component increases MPOD, providing blue light filtration and antioxidant protection
  • Comprehensive antioxidant defense — vitamin C, vitamin E, and zinc provide multi-pathway protection against retinal oxidative stress

What the Research Says

The AREDS2 trial (2013, JAMA) is the definitive study on nutritional supplementation for AMD. Sponsored by the NIH National Eye Institute, it enrolled 4,203 participants aged 50-85 with intermediate AMD or advanced AMD in one eye. The study confirmed that lutein/zeaxanthin was a safe and effective substitute for beta-carotene, eliminating the lung cancer risk in smokers. A 10-year follow-up (Chew et al., 2022) confirmed that the lutein/zeaxanthin formulation outperformed beta-carotene for AMD prevention.

Related Conditions

Macular DegenerationEye HealthAdvanced Amd Prevention
Full AREDS2 Formula Guide

References

  1. (). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. DOI
  2. (). Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmology. DOI
  3. (). A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Archives of Ophthalmology. DOI